"In the first part of the study [with 75 patients], the cohort receiving two doses via intradermal (vs. intramuscular) vaccination, 13/13 subjects produced strong anti-ebola antibody responses. The second stage of the study will evaluate number of doses, lower doses and a combination with DNA-based IL-12," Kolbert wrote in an Aug. 11 research report.
"The intradermal approach is also being evaluated for Inovio's Zika vaccine, now in a human study," Kolbert wrote.
While Kolbert acknowledges that Inovio's Ebola, Zika and MERS programs continue to make progress, "our focus remains on VGX-3100 and the start of the pivotal program, hopefully by YE16." VGX-3100 targets cervical dysplasia.
On Aug. 16, Inovio announced it had licensed a veterinary vaccine for foot and mouth disease (FMD) to South Korean firm Plumbline Sciences. "Plumbline will fund all development activities for this FMD vaccine," Inovio's press release states. Inovio will receive "milestone payments" and royalties on sales in Asia, excluding Japan, according to the release.
The licensing agreement, Inovio's second with Plumbline, enables the company to "focus on human immunotherapies to fight cancers and infectious diseases, we want to monetize non-core assets," according to CEO Dr. J. Joseph Kim.
Inovio has also released its Q2/16 financial results; details are available here.
Read what other experts are saying about:
Want to read more Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent interviews with industry analysts and commentators, visit our Streetwise Interviews page.
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She owns, or her family owns, shares of the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: Inovio Pharmaceuticals Inc. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview or article until after it publishes.
Maxim Group, Inovio Pharmaceuticals Inc. Research Report, August 11, 2016
I, Jason McCarthy, Ph.D., attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.
I, Jason Kolbert, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer.
Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.
The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm’s total revenues, a portion of which is generated by investment banking activities.
Maxim Group makes a market in Inovio Pharmaceuticals Inc
Maxim Group received compensation for investment banking services from Inovio Pharmaceuticals Inc in the past 12 months.
Maxim Group expects to receive or intends to seek compensation for investment banking services from Inovio Pharmaceuticals Inc in the next 3 months.